Identification of Novel Mutations in HEXA Gene in Children Affected with Tay Sachs Disease from India

Mehul Mistri1, Parag M Tamhankar2,*, Frenny Sheth1, Daksha Sanghavi2, Pratima Kondurkar2, Swapnil Patil3, Susan Idicula-Thomas3, Sarita Gupta4, Jayesh Sheth1#

1 FRIGE Institute of Human Genetics, Ahmedabad, Gujarat, India, 2 ICMR Genetic Research Center, National Institute for Research in Reproductive Health, Mumbai, Maharashtra, India, 3 Biomedical Informatics Center, National Institute for Research in Reproductive Health, Mumbai, Maharashtra, India, 4 Department of Biochemistry, M.S. University, Vadodara, Gujarat, India

Abstract

Tay Sachs disease (TSD) is a neurodegenerative disorder due to β-hexosaminidase A deficiency caused by mutations in the HEXA gene. The mutations leading to Tay Sachs disease in India are yet unknown. We aimed to determine mutations leading to TSD in India by complete sequencing of the HEXA gene. The clinical inclusion criteria included neuroregression, seizures, exaggerated startle reflex, macrocephaly, cherry red spot on fundus examination and spasticity. Neuroimaging criteria included thalamic hyperdensities on CT scan/T1W images of MRI of the brain. Biochemical criteria included deficiency of hexosaminidase A (less than 2% of total hexosaminidase activity for infantile patients). Total leukocyte hexosaminidase activity was assayed by 4-methylumbelliferyl-N-acetyl-[β-D-glucosamine lysis and hexosaminidase A activity was assayed by heat inactivation method and 4-methylumbelliferyl-N-acetyl-[β-D-glucosamine-6-sulphate lysis method. The exons and exon-intron boundaries of the HEXA gene were bidirectionally sequenced using an automated sequencer. Mutations were confirmed in parents and looked up in public databases. In silico analysis for mutations was carried out using SIFT, Polyphen2, MutationT@ster and Accelrys Discovery Studio softwares. Fifteen families were included in the study. We identified six novel missense mutations, c.340 G>A (p.E114K), c.964 G>A (p.D322N), c.964 G>T (p.D322Y), c.1178C>G (p.R393P) and c.1385A>T (p.E462V), c.1432 G>A (p.G478R) and two previously reported mutations. c.1277_1278insTATC and c.508C>T (p.R170W). The mutation p.E462V was found in six unrelated families from Gujarat indicating a founder effect. A previously known splice site mutation c.805+1 G>C and another intronic mutation c.672+30 T>G of unknown significance were also identified. Mutations could not be identified in one family. We conclude that TSD patients from Gujarat should be screened for the common mutation p.E462V.

Introduction

Tay Sachs disease (TSD) (MIM# 272800) is an autosomal recessive neurodegenerative disorder due to β-hexosaminidase A deficiency caused by mutation in the HEXA gene (MIM# 606669) encoding the α subunit of hexosaminidase A, a lysosomal enzyme composed of α and β polypeptides [1]. The clinical picture ranges from the acute infantile form rapidly leading to death to progressive later onset form compatible with a longer survival. Clinical features include neuroregression, generalized hypotonia, exaggerated startle response and cherry-red spot seen on fundus examination. Affected patients have deficient enzyme activity of Hexosaminidase A (Hex A) in leukocytes or plasma [2]. The human HEXA gene is located on chromosome 15 q23-q24 with 14 exons. Nearly 130 mutations have been reported so far in the HEXA gene to cause TSD and its variants, including single base substitutions, small deletion, duplications and insertions splicing alterations, complex gene rearrangement and partial large duplications (http://www.hgmd.cf.ac.uk/). Most of these mutations are private mutations and have been present in a single or few families. Only few mutations have been commonly found in particular ethnicities or geographically isolated populations. In the Ashkenazi Jews, 94 to 98% patients are caused by one of the three common mutations c.1277_1278insTATC, c.1421+1 G>C and c.805 G>A (p.G269S) [3–5]. Among the non-Ashkenazi TSD patients the mutations pattern is completely different. A 7.6 kb deletion which includes the entire exon 1 and parts of the flanking sequence, is the major mutation causing TSD in the French Canadian population [4]. The c.571–1 G>T accounts for 80% of mutant alleles among Japanese patients with TSD [1]. The c.1277_1278insTATC and the c.805 G>A (p.G269S) mutations are also commonly found in non-Ashkenazi Jewish populations, along with an intron 9 splice site mutation (c.1073+1 G>A) and the 7.6 kb French Canadian deletion. About 35% of non-Jewish individuals carry one of the two pseudodeficiency alleles; c.739C>T (p.R247W) and c.745C>T (p.R249W), which are not associated with neurological manifestations, since
Table 1. Clinical, biochemical and molecular details of the Indian patients with Tay Sachs disease.

| S no | Age at diagnosis | Native State | Consanguinity | Hex-A activity (MUGS) (nmol/hr/mg) = (x) | Total Hex activity (MUG) = (y) | Hex A % = (x/y) X 100 | Genotypes (nucleotide level) | Genotypes (protein level) |
|------|------------------|--------------|---------------|----------------------------------------|-----------------------------|-----------------------|-------------------------|--------------------------|
| 1    | 11 months        | Gujarat      | No            | 4.5                                    | ND                          | -                     | c.1385A>T/c.1385A>T    | p.E462V/p.E462V          |
| 2    | 1.5 Yrs          | Gujarat      | No            | 4.8                                    | 1827.6                      | 0.2                   | c.1385A>T/c.1385A>T    | p.E462V/p.E462V          |
| 3    | 1 Yrs            | Gujarat      | No            | 5.9                                    | 2208.9                      | 0.26                  | c.1385A>T/c.1385A>T    | p.E462V/p.E462V          |
| 4    | 1.5 Yrs          | Gujarat      | No            | 5.1                                    | 2009                        | 0.25                  | c.1385A>T/c.1385A>T    | p.E462V/p.E462V          |
| 5    | 1.5 Yrs          | Gujarat      | No            | 5.8                                    | 2288                        | 0.25                  | c.1385A>T/c.1385A>T    | p.E462V/p.E462V          |
| 6    | 11 months        | Gujarat      | No            | 0.0 Father -60% (HLC)                   | 2131.0 731.7 528.3 Mother -53% (HLC) | 0.0 - - | c.1385A>T/c.1385A>T | p.E462V/p.E462V |
| 7    | 2.5 Yrs          | Uttar Pradesh| No            | 4.08                                   | 1453.0                      | 0.28                  | c.964 G>A/c.964 G>A    | p.D322N/p.D322N          |
| 8*   | 15 months        | Uttar Pradesh| No            | 0.0                                    | 716.2                        | 0.0                   | Father and mother - [c.964 G>T/-] | p.D322Y/- |
| 9    | 10 months        | Maharashtra  | No            | 23.8                                   | 1840.2                      | 1.29                  | c.340 G>A/c.340 G>A    | p.E114K/p.E114K          |
| 10   | 1 Yrs            | Maharashtra  | No            | 7.2                                    | 2100                        | 0.3                   | c.672+30T>G/c.1432 G>A | Undetermined/p.G478R    |
| 11   | 18 months        | Tamil Nadu   | Yes           | 17.2                                   | 2054.5                      | 0.83                  | c.1178 G>C/c.1178 G>C  | p.R933P/p.R933P          |
| 12*  | 1 Yrs            | Andhra Pradesh| Yes           | Father- 59.3% (HLC)                     | ND                          | -                     | Father - [c.805+1 G>C/-] | Mother - [c.805+1 G>C/-] |
| 13   | 1.5 Yrs          | Iraq         | Yes           | 18.4                                   | 1776.9                      | 1.03                  | c.508C>T/c.508C>T      | p.R170W/p.R170W          |
| 14   | 1 Yrs            | Karnataka    | Yes           | 1.5                                    | 1660                        | 0.09                  | Not found               | -                        |
| 15   | 16 months        | Gujarat      | No            | 2.1                                    | ND                          | -                     | Father and mother - [c.1277_1278insTATC/-] | - |

*DNA of index case is not available, HLC-heat labile activity in carrier parents, ND – not done.

Normal total hexosaminidase values using MUG substrate in our controls ~703 to 1785 nmol/hr/mg protein, normal hexosaminidase A levels ~(62 to 77%); normal MUGS activity 80 to 390 nmol/hr/mg.

doi:10.1371/journal.pone.0039122.t001
Figure 1. (a) – (e): Sequence Chromatogram of mutations Fig. 1a: c. 340 G>A (p.E114K)(homozygous); Fig. 1b: c.508C>T (p.R170W)(homozygous); Fig. 1c: c.964 G>A (p.D322N)(homozygous); Fig. 1d: c.964 G>T (p.D322Y)(heterozygous); Fig. 1e: c.1178 G>C (p.R393P) (homozygous); Fig. 1f: c.1385A>T (p.E462V) (homozygous); Fig. 1g: c.1432 G>A (p.G478R)(heterozygous); Fig. 1h: c.672+30T>G (heterozygous); Fig. 1i: c.805+1G>C. doi:10.1371/journal.pone.0039122.g001
their presence causes the reduction of Hex A activity only towards the artificial substrate but not to the natural GM2 ganglioside [6]. The mutations responsible for TSD in Indian patients are hitherto unpublished.

Results

Fifteen families were included in the study. Consanguinity in parents was present in 4/15 (26.7%) families. The mean age at presentation was 16.6 months (+/− 5.4). All patients had seizures, neuroregression, exaggerated startle reflex, cherry red spot on fundoscopy, axial hypotonia, increased peripheral limb tone and brisk tendon reflexes. None of the patients had hepatosplenomegaly. Neuroimaging in form of computed tomography (CT scan) or magnetic resonance imaging (MRI) of the brain of the proband was available in 10/13 patients and showed characteristic findings of putaminal hyperintensity and thalamic hypointensity in CT scan or T2 weighted images of MRI of the brain. There were no white matter abnormalities. Significant deficiency of Hex A activity was observed in the leukocytes of all thirteen patients and only carrier detection (% Hex A) could be performed in two families where the proband was not alive (Table 1).

The DNA of fourteen such affected TSD families did not have the common mutations c.1277_1278insTATC, c.1421+1G>C, c.805 G>A (p.G269S), 7.6 kb deletion or the two pseudodeficiency mutations c.739C>T (p.R247W) and c.745C>T (p.R249W). The common mutation c.1277_1278insTATC was detected by screening in one family and was confirmed by sequencing. Complete sequencing analysis revealed nine different mutations in thirteen families and could not identify any mutation in one family. We identified six novel deleterious missense mutations, c.340 G>A, c.964 G>A, c.1178C>G and c.1305A>T, c.1432 G>A, that resulted in amnio acid changes p.E114K, p.D322N, p.D322Y, p.R393P, p.E462V, p.G478R [refer to Figure 1(a)–(d)]. We also identified known pathogenic mutations c.508C>T (p.R170W), c.805+1G>C, and another intronic variant c.672+30T>G of undefined significance (refer to Table 1). The novel mutations were not found in 100 control individuals. The missense mutations were not found in the 1000 Genome Project. The intronic variant c.672+30T>G (rs117160567) was found in 1000 Genome Project (Minor Allele Frequency/Minor Allele Count: C = 0.09/20). The mutation c.1305A>T (p.E462V) was found in the homozygous state in six acute infantile TSD patients belonging to unrelated families with common ethnicity (from Gujarat) indicating a founder effect. Haplotypic analysis was performed by sequencing the introns 1, 5, 12, 13 and a 417 basepair region 3' to HEXA gene which contained several polymorphic markers, in all TSD patients and 30 ethnic controls. Table 2 reveals the haplotypes unique to the

| 3' to HEXA gene(a) | Al | Intron 13 (b) | Al | Intron 12 (c) | Al | Intron 5 (d) | Al | Intron 1 (e) | Al |
|-------------------|----|---------------|----|---------------|----|---------------|----|---------------|----|
| rs35949555 T      |    | rs12904378    | C  | rs74020947    | G  | rs191809305  | A  | rs191094610  | A  |
| rs11629508 C      |    | rs113387077   | A  | rs57733983    | T  | rs188570040  | T  | rs188410016  | C  |
| rs76075374 C      |    | rs29122127    | G  | rs189856670   | A  | rs60920713   | C  | rs186683578  | A  |
| rs62088568 G      |    | rs190224431   | G  | rs140288703   | G  | rs59427837   | C  | rs184065715  | T  |
| rs112626309 T     |    | rs112806142   | T  | rs111680766   | A  | rs12593333   | A  | rs4470105    | C  |
| rs3087652 G       |    | rs890313      | G  | rs147324677   | C  | rs1259277    | T  | rs78278321   | G  |
| rs111827252 C     |    | rs113941121   | C  | rs4776594     | G  | rs76530364   | T  | rs575756777  | C  |
| rs75015614 T      |    | rs34085965    | A  | rs7901720     | C  | rs80931124   | T  | rs78970750   | A  |
| rs62022857 C      |    | rs2303448     | C  | rs113665670   | CTCT | rs78905885  | A  | rs4777502    | C  |
| rs149948017 T     |    | rs4777502     | C  | rs74733827    | A  | rs80238386   | G  | rs147502219  | T  |
| rs140091006 G     |    | rs77154656    | C  | rs78097627    | C  | rs145012038  | C  | rs149092488  | G  |
| rs149092488 G     |    | rs77511366    | A  | rs74325922    | G  | rs74787391   | C  | rs74787391   | C  |

(Al = allele).

Region (a) = 417 bp region 3’ to HEXA gene (chromosome 15 plus strand: 72635626 to 72636042); region (b) = 405 bp region in intron 13 of HEXA gene (chromosome 15 plus strand: 72637019 to 72637423; and 567 bp region in intron 13 of HEXA gene (chromosome 15 plus strand: 72637428 to 72637994); region (c) = 489 bp region in intron 12 of HEXA gene (chromosome 15 plus strand: 72638306 to 72638794); region (d) = 424 bp region in intron 5 of HEXA gene (chromosome 15 plus strand: 72639456 to 72639879); region (e) = 405 bp region in intron 1 of HEXA gene (chromosome 15 plus strand: 72656456 to 72656950 and 461 bp region in intron 1 of HEXA gene chromosome 15 plus strand: 72659130 to 72659590). The chromosome coordinates are as per Human Genome Assembly Feb 2009 (GRCh37/hg19).

doi:10.1371/journal.pone.0039122.t002
founder mutation and not found in other patients and 30 ethnic controls. The founder mutation was screened in 500 individuals using ARMS-PCR (amplification refractory mutation system-polymerase chain reaction) and two individuals were found to be carriers for this mutation leading to an allele frequency of 1/500. The ARMS method used the primers 5’-CCAGTTTGTGGTGCACATATT-3’ (mutation specific primer) and 5’-AGTTACCCCACTAACCAGACTG-3’ (common forward primer) in a PCR reaction to show presence of p.E462V allele (123 base pair PCR product) and the primers 5’-CCAGTTTGTGGTGCACATATT-3’ (wild type specific primer) and the common forward primer in another PCR reaction to show presence of wild type allele (123 base pair PCR product). Carriers were confirmed by sequencing.

The Sorting Tolerant from Intolerant (SIFT) index (available at http://sift.jcvi.org/), Polyphen2 scores (available at http://genetics.bwh.harvard.edu/pph2/) and MutationT@ster (available at http://www.mutationtaster.org/) scores for the non-synonymous single nucleotide substitutions are given in Table 3. [7-9] The predictions of the SIFT, Polyphen2 and MutationT@ster algorithms were in concordance with the observed pathogenicity in case of mutations p.E114K, p.R170W, p.D322N, p.D322Y, and p.E462V. The RMSD (Root mean square deviation) values for the modeled mutants were significant for pathogenicity for all missense mutations except p.E114K (refer to Table 3 and Figure 2). This mutation was determined pathogenic by SIFT and Polyphen analysis. The docking studies reveal that the residues Asp322, Tyr421, Arg178, Glu462 play a crucial role in the binding and orientation of GalNAc (refer to Figure 3 and Tables 3, 4 and 5).

The intronic mutation c.672+30T>G was evaluated for pathogenicity using MutationT@ster. The mutation was predicted to lead to gain of aberrant donor splice site at position c.672+35 (score 0.5). However no functional studies could be carried out further since the family was not available later for further testing. It was not found in 100 controls with normal Hex A values. Another intronic mutation c.805+1 G>C disrupts the normal donor splice site of the intron 7. This was found in a consanguineous carrier couple from Andhra Pradesh with history of a previous child being affected with Tay Sachs disease (refer to Table 1).

Discussion

The clinical and neuroimaging features of infantile Tay Sachs disease seen in our patients were consistent with the defined phenotype. The results of enzyme activity measurements (Hex A expressed as percentage of total Hex activity) varied from 0% to 1.29%. This is consistent with previous observations that infantile TSD patients have values ranging from 0 to 2% [10]. Recent studies in patients from India have revealed similar values in infantile TSD patients [11]. Our study indicates that the known deleterious common mutations c.1278insTATC, c.1421+1G>C, c.805G>A (p.G269S), 7.6 kb deletion and the two pseudo-deficiency mutations c.739C>T (R247W) and c.745C>T (R249W) are not common in Indian TSD patients.

We found three novel deleterious mutations (p.D322N, p.D322Y, p.E462V) occurring at the functionally active site of the alpha subunit of hexosaminidase A. The mutation p.R393X has been previously identified in infantile TSD patients from Persia, Turkey and Iraq populations [12-14]. The mutation p.E114K is proximal to the N-glycosylation site α-N115.

We were especially interested in analyzing the c.1385 T>A (p.E462V) mutation because it was identified in six unrelated families from one ethnic group but, to our knowledge, has never
been identified in TSD patients of other ethnic origin. The sequence alignment of Hex A from various species (refer to Figure 4) reveals that the residue E462 is highly conserved. The RMSD of the modeled mutant is also significantly higher as compared to the wild-type protein (refer to Table 1 and Figure 2). This mutation was present in homozygous state in all six patients exhibiting infantile TSD. This is in accordance with previous observations that missense mutations responsible for infantile TSD were generally located in a functionally important region, such as the active site and the dimer interface [15].

The mutation c.508C>T (p.R170W) has been previously reported in different ethnic groups [Japanese, French-Canadian (Estree region, Quebec) and Italian patients] [16–18]. The side chain of R170 in domain II forms a hydrogen bond with the E141 in domain I. The substitution of R with W with a bulkier side chain has a large effect on the interface of domains I and II. This would destabilize the domain interface and cause degradation of the α-subunit [16], [19].

The intronic mutation c.672+30T>G has been previously reported in an obligate carrier individual detected on biochemical screening. The mutation has been reported to be benign in this paper as it was found in combination with another disease causing mutation in an obligate carrier [20]. The National Center for Biotechnology Information (NCBI) single nucleotide polymorphism database (dbSNP) [http://www.ncbi.nlm.nih.gov/SNP/index.html] revealed that the minor allele count of this polymorphism (rs117160567) is minimal (C = 0.0103/13). However this allele has not been reported in homozygous state till date. Thus, the pathogenic potential of this mutation remains to be explored by functional analysis. The presence of another HEXA mutation in this patient in form of large heterozygous deletion or mutation in regions not analyzed like deep intronic and promoter cannot be ruled out.

The splice site mutation c.805+1G>C has been reported previously from Portuguese patients [21]. Another substitution at the same nucleotide c.805+1G>A is common in French-Canadian patients from the Quebec region in Canada [22]. Both mutations are known to be associated with the infantile form of TSD.

In one of our patients, no mutation could be identified. Complete gene sequencing strategy is likely to miss large heterozygous deletions or gene rearrangements. Southern blot analysis or multiplex ligase dependent probe amplification (MLPA) based methods to detect these changes were not available to us.

A large number of gene mutations causing TSD have been previously reported in the HEXA mutation database http://www.hexdb.mcgill.ca/. Among them, mutations resulting in gross alterations in the Hex α-subunit sequence are generally found in the severe infantile form. However, missense mutations causing amino acid substitutions have been found in both the infantile and late onset phenotypes [23]. Mahuran et al, (1999) reported that the detrimental effect of most mutations is on overall folding and/or transport of the protein rather than on the functional sites [24]. Some of the mutations identified in our series affect crucial active residues or cause significant structural aberrations leading to the infantile form of the disease.

Conclusion

The mutations responsible for Tay Sachs disease in Indian population are unique. Patients originating from Gujarat state
could be screened for the founder mutation p.E462V. Except for this mutation, the rest of the mutations were non-recurrent. However, screening for the above mutations would be recommended for cost-effective testing of TSD patients.

**Methods**

**Ethics Statement**

The study protocol was approved by Ethics Committee of Foundation for Research in Genetics and Endocrinology, Ahmedabad, Gujarat (Reg No- E/13237).

**Study Subjects**

Clinical details were noted in a case record form and an informed written consent was obtained from each family. The clinical criteria for inclusion in this study was history of neuroregression, exaggerated startle reflex, cherry red spots on fundus examination and relative macrocephaly. Neuroimaging criteria included presence of gray matter disease shown by hyperintensity in basal ganglia and/or hypointensity in thalamus in T2 weighted images of MRI of the brain. Five ml peripheral blood was collected from the patients for leukocyte enzyme assay and DNA extraction. Leukocyte hexosaminidase A activity was

---

**Figure 3. Stereoscopic view of the docking experiments.** Green sticks indicate Cα trace of amino acids involved in the active site and CPK (Corey-Pauling-Koltun) coloring scheme represents ligand GalNAc (N acetyl galactosamine) portion of GM2 ganglioside. Fig 4a: Wild type (ωHex-A-GalNAc complex). Fig 4b: Mutant (ωD322N-GalNAc), Red shows mutation p.D322N, Fig 4c: Mutant (ωD322Y-GalNAc), Cyan shows mutation p.D322Y, Fig 4d: Mutant (ωE462V-GalNAc), yellow shows mutation p.E462Y.

doi:10.1371/journal.pone.0039122.g003
Table 4. Hydrogen bond interaction for the wild type and Mutant complexes.

| Complex            | Protein (Residue:Atom) | Ligand Atom |
|-------------------|------------------------|-------------|
| Wild Type-GalNAc  | ARG178:HH12 O2         |             |
|                   | ARG178:HH22 O2         |             |
|                   | TYR421:HH             | O6          |
|                   | TRP460:HE1            | O6          |
|                   | ASP207:OD1            | H26         |
|                   | GLU323:OE1            | H28         |
|                   | GLU462:OE2            | H29         |
|                   | HIS262:NE2            | H30         |
|                   | ASP322:OD2            | H20         |
| αD322N-GalNAc      | ARG178:HH22 O1         |             |
|                   | GLU462:OE2            | H26         |
|                   | HIS262:NE2            | H29         |
| αD322Y-GalNAc      | ARG178:HH22 O1         |             |
|                   | GLU462:OE2            | H26         |
|                   | GLU323:OE2            | H28         |
|                   | GLU462:OE2            | H29         |
| αE462V-GalNAc      | ARG424:HH21 O6         |             |
|                   | GLU323:OE2            | H27         |
|                   | GLU323:OE1            | H28         |

doi:10.1371/journal.pone.0039122.t004

determined by manual fluorimetric enzyme assay. Total hexosaminidase (Hex) was measured from the hydrolysis of the synthetic substrate 4-methylumbelliferyl-N-acetyl-β-D-glucosamine (MUG), which releases fluorescent 4-methylumbelliferyl when acted upon by β-hexosaminidase. Hexosaminidase B (Hex B) was determined as the activity left after samples were heated for three hours at 50°C. This procedure led to the loss of Hex A which is heat-labile but not of hexosaminidase B (Hex B) or intermediate isoenzyme. Therefore, Hex A activity was obtained after subtracting Hex B activity from total Hex activity. Hex A was also assayed with the more specific sulphated substrate 4-methylumbelliferyl-N-acetyl-β-D-glucosamine-6-sulphate (MUGS) [25]. Hex A activity (obtained from MUGS lysis) was expressed as percentage of total Hex activity (obtained from MUG lysis).

Screening Procedure for Common Mutations

Genomic DNA was extracted by the standard salting out method. Primary screening of the common mutations was performed by amplification refractory mutation system – polymerase chain reaction (ARMS PCR) using normal and mutant primers as a reverse primers and common forward primers as previously described [26], [27]. PCR amplification was performed for each mutation separately in a 15 μl final reaction volume containing 500 ng genomic DNA, 10× Cetus buffer, 2.0 mM dNTPs, 1 U Taq polymerase, 4–6 pmol of each primer and 1.5 μl 10× Cetus buffer. The thermocycling conditions were 10 min at 94°C, followed by 25–32 cycles of amplification consisting 30 s–60 s at 94°C, 30 s–60 s at 55–65°C and 30 s–3 min at 72°C, and a final elongation for 10 min at 72°C and PCR product were run on 2% agarose and visualized under ultraviolet transilluminator.

Molecular Analysis of HEXA Gene

The exonic and intronic flanking sequence of the HEXA gene were PCR amplified in 14 fragments using previously described primers [28]. DNA amplification was performed for each fragment in a 10 μl final volume containing 100 ng genomic DNA, 1 mM dNTPs, 10 pmol of each primer, 1 U Taq polymerase and 1 μl 10 X PCR buffer. Thirty cycles of amplification were used, each consisting 1 min denaturation at 94°C, 45 s annealing at 60–65°C suitable for each exons and 45 s extension at 72°C in a thermal cycler. Final extension time was 10 minutes. Negative control PCR tubes contained all of the above ingredients except DNA. PCR products were then electrophoresed in 2% agarose along with the appropriate negative controls and a 100 base-pair DNA ladder. Products that passed this quality check were purified by treatment with Exo-SAP-IT™ (USB Corporation, OH, USA) and then sequenced using BigDye Terminator v3.1 and capillary electrophoresis was performed using an automated sequencer ABI-3130 (Applied Biosystems, CA, USA). Mutations were described according to mutation nomenclature, considering nucleotide +1 the A of the first ATG translation initiation codon. Nucleotide numbers are derived from cDNA HEXA sequence (RefSeq cDNA NM_000520.4). Putative mutations were confirmed in two separate PCR products from the patient’s DNA. Heterozygosity for these mutations was confirmed in the parents. The mutations identified were then looked up in public databases like The Human Gene Mutation Database (http://www.hgmd.cf.ac.uk), dbSNP (http://www.ncbi.nlm.nih.gov/SNP/index.html) and McGill University database (http://www.hexdb.mcgill.ca). Novel variants were also ruled out as polymorphism by sequencing the corresponding exons/introns in 100 normal unrelated individuals.

In Silico Analysis

Prediction of functional effects of non-synonymous single nucleotide substitutions (nsSNPs) was done using softwares SIFT (Sorting Intolerant From Tolerant) (available at http://sift.jcvi.org/), Polyphen2 (Polymorphism Phenotyping v2) (available at http://genetics.bwh.harvard.edu/pph2/) and MutationTaster (available at http://www.mutationtaster.org/). [7–9] HumVar-trained prediction model of Polyphen2 was used for distinguishing mutations with drastic effects from all the remaining human variation, including abundant mildly deleterious alleles. Evolutionary conservation of the amino acid residues of Hex A was analyzed using ChustalW program available online at http://www.uniprot.org/help/sequence-alignments.

Structural Studies

Protein Preparation. The mutants (αD322N, αD322Y, αE462V) were built using build mutant protocol of Accelrys Discovery studio 2.0 using the crystallographic structure of Hex A c.1277-1278insTATC, c.1421+1 G>C, 7.6 kb deletion, the pseudo-deficiency alleles (p.R247W and p.R249W) was performed by amplification refractory mutation system – polymerase chain reaction (ARMS PCR) using normal and mutant primers as a reverse primers and common forward primers as previously described [26], [27]. PCR amplification was performed for each mutation separately in a 15 μl final reaction volume containing 500 ng genomic DNA, 10× Cetus buffer, 2.0 mM dNTPs, 1 U Taq polymerase, 4–6 pmol of each primer and 1.5 μl 10× Cetus buffer. The thermocycling conditions were 10 min at 94°C, followed by 25–32 cycles of amplification consisting 30 s–60 s at 94°C, 30 s–60 s at 55–65°C and 30 s–3 min at 72°C, and a final elongation for 10 min at 72°C and PCR product were run on 2% agarose and visualized under ultraviolet transilluminator.

Table 5. Ligand Binding Energy Details for wildtype and mutant α subunits.

| Complex            | Binding Energy (kcal/mol) |
|-------------------|--------------------------|
| Wild Type-GalNAc  | −115.94                  |
| αD322N-GalNAc      | −38.87                   |
| αD322Y-GalNAc      | −52.22                   |
| αE462V-GalNAc      | −80.88                   |

doi:10.1371/journal.pone.0039122.t005
Ligand Preparation. The structural coordinates of GM2 ganglioside was retrieved from the PubChem database (CID 9898635). The GalNAc (N-acetyl galactosamine) portion of the GM2 ganglioside was considered for docking on the active site of Hex A as reported previously [29]. It was prepared using the Prepare Ligands protocol of Accelrys Discovery studio 2.0.

Molecular Docking. Structural analysis revealed that residues R178, D207, H262, E323, D322, W373, W392, Y421, N423, R424 and E462 constitute the active site of Hex A. This information was used to define the binding site and docking studies were performed using the LigandFit protocol of Accelrys Discovery studio 2.0. The potential energy and Root Mean
Square Deviations (RMSD) of the mutant structures with respect to the wild-type structure were calculated. RMSD values more than 0.15 were considered as significant structural perturbations that could have functional implications for the protein [15].

Acknowledgments

We would like to thank the Director of NIRRH, Dr. Sanjiva Khokute for his support. We also thank Rochelle Tixeira for technical assistance. We thank the families of patients with Tay Sachs disease for their participation in this research.

Author Contributions

Conceived and designed the experiments: PMT JS SIT SG. Performed the experiments: PMT MM FS DS PK SP SIT SG. Analyzed the data: MM PMT JS SIT SP. Contributed reagents/materials/analysis tools: PMT JS FS SG. Wrote the paper: PMT MM JS FS.

References

1. Tanaka A, Fujimaro M, Chooi K, Ishigaki G (1999) Novel Mutations, including the second most common in Japan, in the B-hexosaminidase A subunit gene, a simple screening of Japanese patients with Tay-Sachs disease. J. Hum. Genet. 44: 91–95.
2. Fernandes Filho JA, Shaproie BE (2004) Tay-sachs disease. Arch Neurol 61: 1466–1468.
3. Myerowitz R, Costigan FC (1988) The major defect in Ashkenazi Jews with Tay-Sachs disease is an insertion in the gene for alpha-chain of beta-hexosaminidase. J Biol Chem 263: 18367–9.
4. Myerowitz R, Hsiai K (1986) Different mutations in Ashkenazi Jewish and non-Jewish French Canadians with Tay-Sachs disease. Science 232 (4758): 1646–1648.
5. Kaback M, Lim Steele J, Dahbolkar D, Brown D, Levy N, et al. (1993) Tay-Sachs disease carrier screening, prenatal diagnosis and the molecular era. An international perspective, 1970–1993. The International TSD data collection Network. JAMA 270: 2307–15.
6. Cao Z, Natowicz MR, Kaback MM, Lim-steele JS, Preence EM, et al. (1993) A second mutation associated with, apparent beta-hexosaminidase A pseudodeficiency: identification and frequency estimation. Am J Hum Genet 53: 1198–1203.
7. Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 4(7): 1073–81.
8. Azhdahak I, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, et al. (2010) A method and server for predicting damaging missense mutations. Nat Methods 7(4): 248–249.
9. Schwarz JM, Rodolspenger C, Schuelke M, Seelow D (2010) MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods 7(8): 575–6.
10. Kaback MM, Desnick RJ (1999) Hexosaminidase A Deficiency. In: Pagon RA, Bird TD, Dolan CR, Stephens K, editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-. Available from http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=tay-sachs
11. Nalini A, Christopher R (2004) Cerebral Glycolipidoses: Clinical Characteristics of 41 Pediatric Patients. J Child Neurol 19(8): 447–452.
12. Akli S, Chelly J, Lacorte JM, Prence E, Kolodny E, et al. (1992) Ten novel mutations in the HEXA gene in non-Jewish Tay-Sachs patients. Hum Mol Genet. 1: 119–127.
13. Ozkara HA, Navon R (1998) At least six different mutations in the HEXA gene, and identification of mutation in the beta-hexosaminidase A subunit gene, and a simple screening of Japanese patients with Tay-Sachs disease. J Hum Genet. 44(2): 91–5.
14. Fernandes M, Kaplan F, Natowicz M, Preence E, Kolodny E, et al. (1992) A new Tay-Sachs disease B1 allele in in exon 7 in two compound heterozygotes each with a second novel mutation. Hum Mol Genet 1: 759–761.
15. Aldi S, Chomel J-C, Lacorte J-M, Bachner L, Kahn A, et al. (1993) Ten novel mutations in the HEXA gene in non-Jewish Tay-Sachs patients. Hum Mol Genet 2: 61–67.
16. Tanaka A, Fujimaro M, Chooi K, Ishigaki G (1999) Novel mutations, including the second most common in Japan, in the beta-hexosaminidase alpha subunit gene, and a simple screening of Japanese patients with Tay-Sachs disease. J Hum Genet. 44(2): 91–5.
17. Fernandez M, Kaplan F, Natowicz M, Preence E, Kolodny E, et al. (1992) A new Tay-Sachs disease B1 allele in in exon 7 in two compound heterozygotes each with a second novel mutation. Hum Mol Genet 1: 759–761.
18. Akli S, Chomel J-C, Lacorte J-M, Bachner L, Kahn A, et al. (1993) Ten novel mutations in the HEXA gene in non-Jewish Tay-Sachs patients. Hum Mol Genet 2: 61–67.
19. Matsuzawa F, Aikawa S, Sakuraba H, Lan HT, Tanaka A, et al. (2003) Structural basis of the GM2 gangliosidosis B variant. J Hum Genet 48(1): 502–9.
20. Triggs-Raine B, Richard M, Wion D, Preence EM, Natowicz MR (1995) Mutational analyses of Tay-Sachs disease: studies on Tay-Sachs carriers of French Canadian background living in New England. Am J Hum Genet 56(4): 870–9.
21. Ribeiro MG, Pinto R, Miranda MC, Suzuki K (1995) Tay-Sachs disease: intron 7 splice junction mutation in two Portuguese patients. Biochim Biophys Acta. 1270(1): 44–51.
22. Hechman P, Boulay B, De Brackeleer M, Andermann E, Melançon S, et al. (1992) The intron 7 donor splice site transition: a second Tay-Sachs disease mutation in French Canada. Hum Genet. 90(4): 402–6.
23. Gravel RA, Kaback MM, Preia RL, Sandhoff K, Suzuki K (1995) The GM2 gangliosidosis. In: Scriverr CR, Beaudet AL, Sly WS and Valle D (Editors), The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill, New York, 3827–3876.
24. Mahuran DJ (1999) Biochemical consequences of mutations causing the GM2 gangliosidosis. Biochim Biophys Acta 1455: 105–130.
25. Wendler M, Sandhoff K (2009) Hexosaminidase assays. Glycocon. J 26(8), 945–952.
26. Kaplan J, Bodily B, Baylcar J and Hechtman P (1991) Allele-specific amplification of genomic DNA for detection of deletion mutations: Identification of a French-Canadian Tay-sachs mutation. J Inher Metab Dis 14: 707–714.
27. Stockley TL, Ray PN (2003) Multiplexed Fluorescence Analysis for mutations causing Tay-Sachs disease in Methods in Molecular Biology: Neurogenetics Methods and Protocols edited by Potter NT Humana Press, vol-217: 131–142.
28. Triggs-Raine B, Richard M, Wion D, Preence EM, Natowicz MR (1995) Mutational analyses of Tay-Sachs disease: studies on Tay-Sachs carriers of French Canadian background living in New England. Am J Hum Genet 56(4): 870–9.
29. Lemieux MJ, Mark BL, Cherney MM, Withers SG, Mahuran DJ, et al. (2006) Crystallographic structure of human β-hexosaminidase A: Interpretation of Tay-Sachs mutations and loss of GM2 ganglioside hydrolysis. J Mol Biol 359: 913–929.